单边和双边的体下深层大脑刺激不同地有利于帕金森病中的冷漠
Yvan M Vachez1, Marie Bahout2,3, Robin Magnard1
1Univ. Grenoble Alpes, Inserm U1216, Grenoble Institut des Neurosciences, Grenoble, France.
The European journal of neuroscience
|February 18, 2025
概括
双边亚thalamic核深度大脑刺激 (STN-DBS) 可以导致帕金森病 (PD) 患者和动物的冷漠. 然而,单边STN-DBS不会导致冷漠,这表明PD治疗的更安全的替代方案.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 运动障碍 运动障碍
背景情况:
- 脑下核深度大脑刺激 (STN-DBS) 是对帕金森病 (PD) 的治疗方法.
- 在PD患者中,STN-DBS与冷漠之间的联系仍在争论中,一些证据表明STN-DBS可能会诱导冷漠.
- 双边与单边STN-DBS对冷漠的不同影响尚不清楚.
研究的目的:
- 为了比较双边与单边STN-DBS对PD患者和动物的冷漠的影响.
- 调查单边STN-DBS的潜力,以规避与双边STN-DBS相关的冷漠感应.
主要方法:
- 经过单边或双边STN-DBS的PD患者的临床随访,评估手术前和后的冷漠.
- 慢性单侧或双侧深度大脑刺激 (DBS) 在动物中,使用行为测试对动机变化的纵向评估.
主要成果:
- 双边STN-DBS被发现可以促进PD患者的冷漠,并诱导动物的动机丧失.
- 单边STN-DBS对PD患者或老鼠的冷漠没有显著影响.
- 这些发现表明STN-DBS横向性对冷漠的不同影响.
结论:
- 双边的STN-DBS,但不是单边的STN-DBS,在帕金森病中促进冷漠.
- 单边STN-DBS可能是一种策略,以避免或减少接受PD治疗的患者冷漠的风险.
- 这项研究强调了刺激参数在预测STN-DBS神经精神病学副作用方面的重要性.
相关概念视频
Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429


